LigaChem secures antibody technology from Go Therapeutics for next-gen ADCs

LigaChem Biosciences said it has signed a licensing agreement with U.S.-based Go Therapeutics to introduce a new antibody platform designed for the development of antibody-drug conjugates (ADCs).

Under the deal, LigaChem Biosciences will gain global rights to develop and commercialize ADCs based on Go Therapeutics’ antibody technology. Financial terms were not disclosed due to confidentiality agreements.

The licensed antibody incorporates Go Therapeutics’ proprietary super-clean target approach, which identifies antigens expressed exclusively on tumor cells and absent in normal cells.

By eliminating on-target toxicity against healthy tissues, the technology aims to overcome one of the major limitations of current solid tumor therapies. The companies expect the antibody to serve as the backbone for novel ADCs addressing high unmet medical needs in cancers such as lung, breast, ovarian, and colorectal.

“Through this partnership with Go Therapeutics, we have already brought in five new oncology antibody targets in 2025 alone,” said LigaChem Biosciences CEO Kim Yong-zu. “We will continue to strengthen strategic collaborations not only in antibody development but also in innovative ADC payloads, thereby building a pipeline of novel ADCs with high global licensing value.”

Go Therapeutics CEO Constantine Theodoropulos also said, “We are excited to work with LigaChem Biosciences on developing first-in-class ADCs that selectively target cancer cells.”

By combining the company’s innovative tumor-targeting technology with LigaChem’s ADC expertise, it hopes to deliver safer and more effective treatments for patients with hard-to-treat solid tumors, Theodoropulos added.

LigaChem Biosciences is pursuing its “Vision 2030” strategy, which calls for securing three to five new ADC candidates annually and moving them rapidly into clinical development. The latest agreement with Go Therapeutics reflects this strategy, with the company aiming for accelerated clinical entry and sustained pipeline expansion.